Pharmaceutical Development and Evaluation of Reservoirtype Ciprofloxacin Ocular Insert



  • Jayesh K Jethva
  • Chintan H Trivedi
  • Sarita P Ratanpara
  • Geeta R Bathwar
  • Ramesh B Parmar


Ocular inserts of ciprofloxacin hydrochloride were prepared with the aim of achieving once a day administration. Drug reservoir was prepared using sodium CMC while rate controlling membrane was prepared using Eudragit RS100 and RL100. Ocular inserts were evaluated for their physicochemical parameters like thickness, weight uniformity, drug content, percent moisture loss, and percent moisture absorption. The in vitro drug release studies were carried out using Bi-chambered donor receiver compartment model.  In vitro drug release kinetic data was treated according to Zero, First, and Higuchi kinetics to access the mechanism of drug release. At the end of 24th hr, in-vitro percentage drug release was obtained for the formulations RF1 was% 46.02 and for RF5 was 98.23%. The drug release from the formulation RF5 (Eudragit RS and RL 100 (1:1)) was 98.23 % at the end of 24th hour which was available as controlled and prolonged. In Kors Meyer Peppas, n value in optimized batch (RF5) was observed 1.399 which indicated super case II transport occurs. All physical parameters evaluated were satisfactory. So formulation RF5 was selected as the best formulation.


Download data is not yet available.


Metrics Loading ...


Ocular inserts, Ciprofloxacin, Eudragit RL100, Eudragit RS100, Kinetic studies




How to Cite

Jethva JK, Trivedi CH, Ratanpara SP, Bathwar GR, Parmar RB. Pharmaceutical Development and Evaluation of Reservoirtype Ciprofloxacin Ocular Insert. Scopus Indexed [Internet]. 2015 Nov. 30 [cited 2024 Jun. 20];8(4):3024-30. Available from:



Research Articles


Chambers, H. F (2001). Sulfonamides, trimethoprim, and quinolones. In Basic and Clinical Pharmacology, Katzung, B. G., Ed.; New York: McGraw Hill: 799.

Gilhotra R, Nagpal K and Mishra D (2011). Azithromycin novel drug delivery system for ocular application. International Journal of Pharmaceutical Investigation, 1: 22-29.

Haders D (2008). New controlled release technologies broaden opportunity for ophthalmic therapy. Drug Delivery Technology; 8: 48-53.

Jain D and Banarjee R (2010). Biodegradable hybrid polymeric membranes for ocular drug delivery. Acta Biomaterial, 6: 1370-1379.

Jeganath S., Viji A and Devi S. (2011). Design and evaluations of controlled release ocuserts of indomethacin. International Journal of Pharmacy and Pharmaceutical Science Research, 2: 80-86.

Karthika K and Padmapreetha J, (2010). Comparative Review on conventional and advanced ocular drug delivery formulations. International Journal of Pharmacy and Pharmaceutical Sciences; 2: 1-5.

Makadia M. (2013). “formulation and evaluation of ocular insert of diclofenac sodium”, S.J. Thakkar Pharmacy College, 4: 47-53.

Mortazavi S and Jaffariazar Z (2010). “Formulation and In-Vitro Evaluation of Ocular Ciprofloxacin-Containing Minitablets Prepared with Different Combinations of Carbopol 974P and Various Cellulose Derivatives”, Iranian Journal of Pharmaceutical Research, 2: 107-114.

Nema R.K and Rathore K.S. (2009). Review on Ocular Inserts. Int J Pharm Tech Res; 1(2): 164-169.

Parmar R and Dr. Tank H (2013). Design Formulation and Evaluation of Reservoir Type Controlled Released Moxifloxacin Hydrochloride Ocular Insert, Asian Journal of Pharmaceutical And Clinical Research Science, 3(1): 19-24.

Rathor K.S and Nema R.K (2009). An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res 1(1):1-5.

Saettone, M. F and Saleminen, L. (1995). Ocular inserts for topical delivery. Adv. Drug Delivery Rev, 16: 95-106.

Shahwal V (2011). Ocular drug delivery: An Overview. International Journal of Biomedical and Advance Research, 2: 167-187.

Upadhyay N, Patidar A and Agrawal S, (2011). Development and evaluation of polymeric sustained release levofloxacin ocuserts. Research Journal of Pharmaceutical, Biological and Chemical Science, 2: 411-521.